Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Short-term Investments: 2017-2025

Historic Short-term Investments for Coherus Oncology (CHRS) over the last 5 years, with Sep 2025 value amounting to $88.3 million.

  • Coherus Oncology's Short-term Investments was N/A to $88.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.3 million, marking a year-over-year change of. This contributed to the annual value of $14.9 million for FY2023, which is 88.41% down from last year.
  • Latest data reveals that Coherus Oncology reported Short-term Investments of $88.3 million as of Q3 2025, which was up 325.72% from $20.7 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Short-term Investments registered a high of $140.0 million during Q1 2021, and its lowest value of $14.9 million during Q4 2023.
  • For the 2-year period, Coherus Oncology's Short-term Investments averaged around $59.7 million, with its median value being $61.3 million (2023).
  • Data for Coherus Oncology's Short-term Investments shows a maximum YoY tumbled of 88.41% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Coherus Oncology's Short-term Investments stood at $108.2 million in 2021, then reached $128.1 million in 2022, then crashed by 88.41% to $14.9 million in 2023, then reached $88.3 million in 2025.
  • Its Short-term Investments stands at $88.3 million for Q3 2025, versus $20.7 million for Q2 2025 and $14.9 million for Q4 2023.